Probiotics prebiotics & - 6th
←
→
Page content transcription
If your browser does not render page correctly, please read the page content below
September 11-13, 2011
ROME
Università Urbaniana
6 probiotics &prebiotics
th
new foods
c hair p e op le of t he me e t in g
L. Capurso
G. Delle Fave
L. Morelli
A. Guarino
6 probiotics&prebiotics
th
new foods
t he me eting is org anised by
O LT RE LA NUTRI ZIO NE
under the pa tronag e of
Ita l ia n Aca d emy fo r t he study of Intestina l Micro biota
SIG E - Soci età Ita lia na d i Ga stro enterologi a
SI NUT - So c i età Ita liana di Nutra ceuti ca
ES PGHAN - Euro pea n So c iety fo r Paedi at r ic G a stroe nte rolog y,
He pa to log y and Nutri tio n
S I GE NP - So ci età Ita l i a na di Ga st roentero logi a E p ato log ia
e Nutr izi one Pedia tr ica
Centro Studi d el l’Ali mentazione
2
INDE X
Sunday, September 11
Aula Magna p. 4
Monday, September 12
Aula Magna p. 6
Aula C p. 8
Aula Newman - Pediatric Day p. 12
Tuesday, September 13
Aula Magna p. 14
Aula C - Oral Communications p. 15
Aula Newman p. 19
Posters p. 20
Abstracts p. 27
Faculty p. 53
Index of Authors p. 57
General Information p. 61
Scientific Information p. 64
Exhibition Area p. 66
3
A ul a M ag n a s unday, Se p t e mb er 1 1
10.00 a.m. - 12.45 p.m. ITALIAN SOCIETY OF GASTROENTEROLOGY - GUT MICROBIOTA STUDY GROUP
President: D. Festi (Italy)
Chairpeople: A. Gasbarrini (Italy), G. Capurso (Italy)
The gut barrier: a complex interplay
A. Gasbarrini (Italy)
LITERATURE UP TO DATE
Gut mucous barrier
E. Scarpellini (Italy)
Neuroenteric system activation
R. De Giorgio (Italy)
Gut barrier and pancreatic diseases
G. Capurso (Italy)
Discussion
REPORT OF ONGOING STUDIES
Microbiota, innate system, and gastrointestinal smooth muscles: ongoing studies
C. Severi (Italy)
The pig model to study IBD-associated intestinal inflammation and
dysbacteriosis: results from a preliminary study
E. Grilli (Italy)
BREAK
Morphology of segmented filamentous bacteria and their patterns of contact
with the follicle-associated epithelium of the mouse terminal ileum: Implications
for the relationship with the immune system
M. Caselli (Italy)
HCV and liver steatosis: viral role and dismetabolic diseases
C. Balsano (Italy)
Gut microbiota, probiotics and liver diseases
C. Loguercio (Italy)
LECTURE
The microbiota in IBS
G. Barbara (Italy)
TAKE HOME MESSAGES
D. Festi (Italy)
4sund ay, S ep t e m be r 11 Aul a M a gn a
03.00 - 03.30 p.m. WELCOME ADDRESS
L. Capurso (Italy)
03.30 - 05.30 p.m. ROUND TABLE
SCIENCE AND GUIDELINES:
10TH YEARS OF FAO GUIDELINES
Chairpeople: R. Marabelli (Italy), L. Morelli (Italy)
G. Delle Fave (Italy)
F. Guarner (Spain)
Y. Sanz (Spain)
M. Serafini (Italy)
05.30 - 07.00 p.m LECTURES
Chairpeople: G. Delle Fave (Italy), A. Guarino (Italy)
Brain-gut axis and intestinal microbiota
S.M. Collins (Canada)
Cellular stress as sensor for luminal factors and the microbiome
D. Haller (Germany)
Functional metagenomics with relevance to host-microbe interactions
J. Dorè (France)
WELCOME COCKTAIL
5A ul a M ag n a Mon day, Se p t em be r 12
08.30 - 10.30 a.m. MICROBIOTA AND INTESTINAL HEALTH
Chairman: R. Crittenden (Finland)
Microbiota in Health and Disease
W.M. de Vos (The Netherlands)
Health Biomarker Bacteria
C. Belzer (The Netherlands)
Microbiota and Diet
A. Salonen (Finland)
Lactobacillus GG - Life After the Genome
R. Kekkonen (Finland)
Round Table Panel: WHAT DO WE NOW KNOW AND HOW CAN WE USE THIS?
R. Crittenden (Finland), C. Belzer (The Netherlands), A. Salonen (Finland),
R. Kekkonen (Finland), W.M. de Vos (The Netherlands)
10.30 - 11.30 a.m. IMMUNOLOGY AND GUT BACTERIA
Chairpeople: M. Rescigno (Italy), F. Pallone (Italy)
Probiotics and immunoregulation
C. Nicoletti (United Kingdom)
Immune modulation by probiotic bacteria in immune-compromised subjects
A. Castellazzi (Italy)
Aging, immunity and intestinal microbiota
E. Mengheri (Italy)
Fermented dairy product containing Lactobacillus casei CNCM I-1518/DN-114 001
reduces the incidence of common infections and modulates the innate immune
response in shift workers
E. Guillemard (France)
11.30 a.m. - 12.30 p.m. LACTOBACILLUS REUTERI: A SINGLE PROBIOTIC FOR SEVERAL INDICATIONS
Chairpeople: C. Cricelli (Italy), M. Koch (Italy)
Probiotics, Gutpain and the Nervous System
J. Bienenstock (Canada)
Role of Lactobacillus reuteri DSM 17938 in the uncomplicated diverticular disease
A. Andriulli (Italy)
Mucosal permeability and immune activation as potential therapeutic targets of
probiotics in irritable bowel syndrome
G. Barbara (Italy)
Role of Lactobacillus reuteri DSM 17938 in the modulation of the bronchial inflammation
in patients with cystic fibrosis
S. Cucchiara (Italy)
12.30 - 01.30 p.m. NON BACTERIAL PROBIOTICS
Chairwoman: M. Elli (Italy)
Use of bacillus spores as probiotics for human use
E. Ghelardi (Italy)
6Mon day, S e pt e m be r 12 Aul a M a gn a
Diet supplementation with Saccahromyces boulardii as a novel strategy to improve
the Metabolic Syndrome in an animal model of obesity
I. Castagliuolo (Italy)
New clinically proven yeast probiotic in the area of IBS
P. Justen (France)
01.30 - 02.30 p.m. LUNCH
02.30 - 04.00 p.m. NUTRIGENOMICS & GUT HEALTH
Chairpeople: P. Louis (United Kingdom), G. Perozzi (Italy)
Nutrigenomics as a tool to discover new functions for "old" molecules in chronic
disease prevention
F. Virgili (Italy)
Inside the adaptation mechanisms of bifidobacteriam to the gastrointestinal environment
A. Margolles (Spain)
Dietary modulation of the human gut microbiota
P. Louis (United Kingdom)
A metagenomic approach to the “fermented food microbiota”
C. Devirgiliis (Italy)
04.00 - 06.00 p.m. INTESTINAL MICROBIOTA AND IBD
Chairpeople: R. Caprilli (Italy), M.A. Gassull (Spain)
Engineering commensal bacteria and plants for the treatment of intestinal inflammation
S. Carding (United Kingdom)
Dysbiosis in IBD and differences in microbiota composition between inflamed and
non inflamed intestine
A. Walker (United Kingdom)
Colonization by faecalibacterium prausnitzii and maintenance of clinical remission
in patients with ulcerative colitis
F. Guarner (Spain)
Probiotics and IBD
M. Rescigno (Italy)
Clinical evidence of probiotic efficacy in IBD
S. Danese (Italy)
Interactions between intestinal microbiota and innate immune system in pediatric
inflammatory bowel disease
S. Cucchiara (Italy)
06.00 - 07.00 p.m. LECTURES
Chairpeople: E. Corazziari (Italy), M. Anti (Italy)
Prebiotics, probiotics and obesity-related disorders
H. Tilg (Austria)
Bacterial overgrowth in IBS: the role for probiotics
T. Karakan (Turkey)
7A ul a C Mon day, Se p t em be r 12
08.30 - 10.00 a.m. NATURAL PRODUCTS AND GUT
Chairpeople: D. Matteuzzi (Italy), N. Caporaso (Italy)
The modern analytical determination of complex mixtures of natural products
M. Nicoletti (Italy)
Bioactivation of dietary phytochemicals by intestinal microbiota and bifidobacteria
M. Rossi (Italy)
Polyphenols and human intestinal microflora: implications for health
G. Scapagnini (Italy)
Gut microbiota and metabolic diseases
M. Serino (Italy)
10.00 - 11.30 a.m. ORAL COMMUNICATIONS 1
Chairpeople: A. Saggioro (Italy), G. Capurso (Italy)
OC 1.1 - PATHOGEN AND PROBIOTIC BACTERIA DIFFERENTIALLY STIMULATE
NITRIC OXIDE PRODUCTION AND S100B PROTEIN EXPRESSION IN HUMAN
ENTEROGLIAL CELLS
Turco Fabio*[1], Sarnelli Giovanni[1], Cirillo Carla[2], Mango Annamaria[1], Nasti Anna[1],
D'Alessandro Alessandra[1], Farina Virginia[1], Cuomo Rosario[1]
[1]
Università Federico II - Napoli, Italy - [2]K.U. Leuven - Leuven, Belgium
OC 1.2 - A PROBIOTIC COMBINATION TO REDUCE ANTIBIOTIC ASSOCIATED
DIARRHOEA AND OTHER SIDE-EFFECTS OF ANTIBIOTIC-USE:
A DOSE-RESPONSE STUDY
Ouwehand Arthur*[1]
[1]
Danisco Sweeteners - Kantvik, Finland
OC 1.3 - ANTI-INFLAMMATORY EFFECTS OF LACTOBACILLUS RHAMNOSUS
(LGG) COUNTERACT LIPOPOLYSACCHARIDE (LPS)-INDUCED PERSISTENT
ALTERATIONS OF HUMAN COLONIC SMOOTH MUSCLE
Ammoscato Francesca*[1], Matarrese Paola[2], Scirocco Annunziata[1], Petitta Chiara[1],
Ascione Barbara[2], Di Natale Giuseppe[3], Marignani Massimo[4], Malorni Walter[2], Severi
Carola[1]
[1]
Gastroenterology Unit A, Dip.Medicina Interna e Specialità Mediche, Università Sapienza - Roma,
Italy [2]Department of Drug Research and Evaluation, Istituto Superiore di Sanità - Roma, Italy -
[3]
Department of Surgery, F. Durante, University ‘‘Sapienza’’ - Roma, Italy - [4]UOC Gastroenterologia,
Ospedale S. Andrea - Roma, Italy
OC 1.4 - BEHAVIOUR OF ENTEROHEMORRHAGIC ESCHERICHIA COLI O157: H7
IN HUMAN SIMULATED DIGESTIVE CONDITIONS AND ANTAGONISTIC
PROPERTIES OF A SACCHAROMYCES CEREVISIAE PROBIOTIC YEAST STRAIN
Etienne-Mesmin Lucie*[1,2], Livrelli Valérie[2], Chassaing Benoit[2], Privat Maud[2], Denis
Sylvain[1], Alric Monique[1], Darfeuille-Michaud Arlette[2], Blanquet-Diot Stéphanie[1]]
[1]
ERT 18, Equipe de Recherche Technologique «Conception, Ingénierie et Développement de
l’Aliment et du Médicament », Université d'Auvergne, Clermont-Ferrand, F-63000, France
[2]
E 2526 USC INRA 2018, Evolution des bactéries pathogènes et susceptibilité génétique de l’hôte,
Université d'Auvergne, Clermont-Ferrand, F-63000, France
8Mon day, S e pt e m be r 12 Aul a C
OC 1.5 - BIFIDOBACTERIUM LACTIS BL-04™ REDUCES SYMPTOMS OF COMMON
COLD IN HEALTHY PHYSICALLY ACTIVE INDIVIDUALS: A RANDOMISED
CONTROLLED TRIAL
Lahtinen Sampo*[1], West Nic[2], Pyne David[2], Horn Peggy[2], Cripps Allan[3], Hopkins
Will[5], Brun Mary[6], Warren Hilary[6], Wu Fan[6], Fricker Peter[2]
[1]
Danisco Health & Nutrition - Kantvik, Finland - [2]Australian Institute of Sport - Canberra, Australia
- Griffith University - Gold Coast, Australia - [5]Auckland University - Auckland, New Zealand -
[3]
[6]
Canberra Hospital - Canberra, Australia
OC 1.6 - HEAT INACTIVATED PROBIOTIC STRAINS SPECIFICALLY STIMULATE
NFK - MAP KINASE PATHWAYS, DIFFERENT MIRNAS AND MATURATION IN CACO
II ENDOTHELIAL CELLS AND IN DENDRITIC CELLS
Ladan Giahi[1], Eva Aumueller[1], Manuela Nestlberger[1], Ibrahim Elmadfa[1], Alexander
Haslberger*[1]
Univ Vienna, Dep. Nutritional Sciences - Vienna, Austria
[1]
OC 1.7 - SUPPLEMENTATION OF YOGURT BY COMMERCIALLY AVAILABLE
BACILLUS CLAUSII ENDOSPORES
Pal Karoly*[1], Szarvas Jozsef [ 4 ] , Hilyakne Kadlott Maria[1], Szen Orsolya[5], Naar Zoltan[1],
Kiss Attila[4]
Eszterhazy Karoly College, Dept. of Food Chemistry and Biochemistry - Eger, Hungary - [4]Eszterhazy
[1]
Karoly College, Dept. of Microbiology and Food Technology - Eger, Hungary - [5]Eszterhazy Karoly College,
EGERFOOD Regional Knowledge Centre - Eger, Hungary
OC 1.8 - GALACTOOLIGOSACCHARIDES PRODUCTION FROM WHEY USING
ENZYME ISOLATED FROM STREPTOCOCCUS THERMOPHILUS AND ASSESSMENT
OF THEIR PREBIOTIC POTENTIAL
Sangwan Vikas*[1], Tomar Sudhir Kumar[1], Ali Babar[1], Singh R.R.B.[1]
[1]
National Dairy Research Institute - Karnal, India
OC 1.9 - DOSE-RESPONSE EFFECT OF BIFIDOBACTERIUM LACTIS HN019 ON
WHOLE GUT TRANSIT TIME AND FUNCTIONAL GASTROINTESTINAL SYMPTOMS
IN ADULTS
Ouwehand Arthur*[1], Waller Philip[2], Gopal Pramod[3], Leyer Greg[4], Reifer Cheryl[5],
Stewart Morgan[5], Miller Larry[5]
[1]
Danisco Sweeteners - Kantvik, Finland - [2]Accurate Clinical Research - Huston, USA -
[3]
Fonterra - Palmerston North, New Zealand - [4]Danisco USA - Madison, USA -
[5]
SPRIM - San Francisco, USA
OC 1.10 - MORPHOLOGY OF SEGMENTED FILAMENTOUS BACTERIA AND THEIR
PATTERNS OF CONTACT WITH THE FOLLICLE-ASSOCIATED EPITHELIUM OF THE
MOUSE TERMINAL ILEUM: IMPLICATIONS FOR THE RELATIONSHIP WITH THE
IMMUNE SYSTEM
Caselli M.[1], Cassol F.[1], Boldrini P.[1], Vaira D.[1], Calò G.[1]
School of Gastroenterology - Department of Experimental and Clinical Medicine; University of
[1]
Ferrara, Ferrara, Italy
OC 1.11 - THE PIG MODEL TO STUDY IBD-ASSOCIATED INTESTINAL INFLAMMATION
AND DYSBACTERIOSIS: RESULTS FROM A PRELIMINARY STUDY
E. Grilli[1], B. Tugnoli[1], A. Zannoni[1], M. L. Bacci[1], M. Forni[1], A. Piva[1]
DSMVET, Faculty of Veterinary Medicine, University of Bologna, Italy
[1]
9A ul a c Mon day, Se p t em be r 12
11.30 a.m - 12.30 p.m. NEW FOODS AND LIVER DISEASE: EVIDENCE IN ANIMAL MODELS
Chairpeople: A.F. Attili (Italy), F. Morisco (Italy)
Coffee components and NAFLD
P. Vitaglione (Italy)
Garlic and liver what news?
G. D'Argenio (Italy)
Nanoparticles and food component delivery
G. Peluso (Italy)
12.30 - 01.00 p.m. LECTURE
Flavonoids probable made of action
M. Serafini (Italy)
01.00 - 01.30 p.m. LECTURE
Probiotics and prebiotics: unconventional use
M. Miraglia del Giudice (Italy)
01.30 - 02.30 p.m. LUNCH
02.30 - 04.00 p.m. NEW FOODS SESSION
Chairman: V. Fogliano (Italy)
Prebiotic and cryoprotective properties of soluble fiber from hazelnut skin: effect
on growth and viability of L. plantarum
M. Arlorio (Italy)
Biological effects of yerba maté
D. Bastos (Brazil)
Whole grain and cardiovascular health
V. Fogliano (Italy)
Effects of dietary starch on the gut microbiota
K.P. Scott (United Kingdom)
Gut in local and systemic anticancer response
L. Vannucci (Czech Republic)
Apple polyphenols and colon cancer
L. Ricciardiello (Italy)
10Mon day, S e pt e m be r 12 Aul a C
04.00 - 05.30 p.m. HEALTH AGEING PERSPECTIVE
Chairpeople: M. Calvani (Italy), F. Marotta (Italy)
Gene-Nutraceutical interplay in a healthy-aging perspective: present tips & future
avenues
F. Marotta (Italy)
Aging and menopausal transition: effects of Klamath algae extracts on well-being
and oxidative status
A.D. Genazzani (Italy)
Proteic malnutrition, aminoacids and elderly
V. Marigliano (Italy)
Exploring the role of “estrogen factor” in ageing men and its modulation through
nutraceutics
A. Polimeni (Italy)
Microbiota and health
M. Calvani (Italy)
11A ul a Ne w man Mon day, Se p t em be r 12
PEDIATRIC DAY
With the endorsement of ESPGHAN
Chairman: A. Guarino (Italy)
08.30 - 10.00 a.m. DETERMINANTS OF MICROFLORA IN CHILDREN AND THEIR
FUNCTIONAL MODIFICATION
Chairpeople: G. Buonocore (Italy), J. Vanderhoof (USA)
Molecular approaches to intestinal microflora
A. Swidsinski (Germany)
Nutrimetabolomics and its applications
V. Fanos (Italy)
Microbiota composition and nutrition effects
P. Lionetti (Italy)
Early immunomodulation by intestinal microflora
L. de Ridder (The Netherlands)
10.00 - 10.30 a.m. LECTURE
Intestinal microbiome and the metabolic consequences in neonates
J.B.H. van Goudoever (United Kingdom)
10.30 - 11.00 a.m. COFFEE BREAK
Chairpeople: F. Indrio (Italy), F. Mosca (Italy), R. Shamir (Israel)
11.00 - 11.30 a.m. LECTURE
Is early intestinal colonization a determinant of obesity?
E. Isolauri (Finland)
11.30 a.m. - 12.00 p.m. LECTURE
The gut barrier: new acquisitions and therapeutical approaches
A. Gasbarrini (Italy)
12.00 - 01.30 p.m. EARLY FUNCTIONAL NUTRITION
Early nutrition for the prevention of atopy
C. Dupont (France)
Intestinal motility and microflora: a novel target for intestinal functional disorders
(probiotics in IBS)
S. Guandalini (USA)
Functional nutrition as adjunctive treatment in Cystic Fibrosis
E. Bruzzese (Italy)
Bifidogenics effects by prebiotics: are they clinically important?
I. Hojsak (Croatia)
12Mon day, S e pt e m be r 12 A ul a Ne w man
01.30 - 02.30 p.m. LUNCH
02.30 - 04.00 p.m. SAFETY AND QUALITY OF INFANT FORMULA AND ITS REGULATION
Chairpeople: M. Giovannini (Italy), H. Szajewska (Poland)
Introduction
P. Aggett (United Kingdom)
True and potential dangers from nutrient-deficient formulae. Lessons from a
thiamine deficient formula
R. Shamir (Israel)
The role of national and international health authorities in the control of infant
formula
V. Di Giorgi Gerevini (Italy)
Functional foods or functional nutrients for infants and children?
C. Agostoni (Italy)
04.00 - 04.30 p.m. COFFEE BREAK
Chairpeople: M. Giovannini (Italy), J.B.H. van Goudoever (United Kingdom)
04.30 - 05.00 p.m. LECTURE
Supplementation of infant formula with probiotics/prebiotics: lessons learned with
regard to documentation of outcomes
H. Szajewska (Poland)
05.00 - 06.30 p.m. FUNCTIONAL FOODS FOR PREVENTION IN THE GENERAL POPULATION AND IN RISK
GROUPS
Clinical effects of PUFA in infant formula
E. Verduci (Italy)
Time course of the bifidogenic effect and its clinical implications
F. Salvini (Italy)
Co-administration of antibiotics and probiotic: what is the purpose
Y. Vandenplas (Belgium)
Functional nutrition in preterm infants
F. Indrio (Italy)
13A ul a m ag n a T ue s day, S e pt e m be r 1 3
08.30 - 11.30 a.m. PROBIOTICS, DIETARY PHENOLICS AND HEALTH
Chairpeople: A. Andriulli (Italy), M. Crespi (Italy)
Microbiota studies from European MetaHIT project
F. Guarner (Spain)
Diet, prebiotics and intestinal microbiota
K. Tuohy (United Kingdom)
Prebiotics and calcium absorption
M.L. Brandi (Italy)
Probiotic benefits for athletes
M. Gleeson (United Kingdom)
The aging gut microbiota: a new perspective
P. Brigidi (Italy)
Antiageing strategies: the role of pre-probiotics and polyphenols from red wine
E. Jirillo (Italy)
Dietary phenolics in human health and disease: from molecular mechanisms to
preventive and therapeutic opportunities
D. Del Rio (Italy)
Predictive biomarkers for response to functional foods
P. Patrignani (Italy)
The microbiota and IBS; from dysbiosis to SIBO, from prebiotics and probiotics
to antibiotics
E. Quigley (Ireland)
11.30 a.m. - 01.00 p.m. CELIAC DISEASE SESSION
Chairpeople: G.R. Corazza (Italy), M. Del Piano (Italy)
Enzyme strategies to detoxify gluten
M. Rossi (Italy)
Gut microbiota analysis of italian children at-risk for celiac disease
C. Catassi (Italy)
Weaning and prevention of food intolerance
M. Silano (Italy)
Gut microbes and gliadin interactions in celiac disease pathogenesis
Y. Sanz (Spain)
14Tu es day, Se p t em be r 1 3 Aul a C
08.30 - 09.30 a.m. FUNCTIONAL MEDICINE AND PRE-PROBIOTICS
Chairman: A. Saggioro (Italy)
An introduction to functional medicine
F. Ongaro (Italy)
Leaky gut and chronic inflammation
A. Saggioro (Italy)
Prebiotics and microbiota health effects
M. Roberfroid (Belgium)
Gut microbiota links gut barrier and metabolic endotoxemia to obesity and
diabetes
P.D. Cani (Belgium)
09.30 - 10.30 a.m. LECTURES
Chairman: G. Fatati (Italy)
Synthesis "in vitro" of antioxidant compounds by enzymatic complexes isolated
from germinated wheat
G.L. Gianfranceschi (Italy)
Probiotics and cytochromes expression
E. Bezirtzoglou (Greece)
10.30 a.m. - 01.00 p.m. ORAL COMMUNICATIONS 2
Chairpeople: M. Marignani (Italy), D. Festi (Italy)
OC 2.1 - COLONIC MUSCLE CONTRACTILE ACTIVITY FOLLOWING EXPOSURE
TO LACTOBACILLUS RHAMNOSUS GG
Guarino Michele[1], Cocca Silvia*[1], Altomare Annamaria[1], Ammoscato Francesca[2],
Alloni Rossana[1], Severi Carola[2], Cicala Michele[1]
[1]
Campus Bio-Medico - Roma, Italy - [2]Università degli Studi "La Sapienza" - Roma, Italy
OC 2.2 - DETECTION, IDENTIFICATION AND QUANTIFICATION OF DIFFERENT
PROBIOTIC STRAINS IN FOOD BY USING A MULTIPLEX QPCR
Herbel Stefan*[1], Günther Sebastian[3], Wieler Lothar H.[2]
Stefan Roland Herbel - Berlin, Germany - [2]Lothar H. Wieler - Berlin, Germany - [3], Sebastian
[1]
Günther - Berlin, Germany
OC 2.3 - EVALUTATION OF PROBIOTIC BACTERIAL ADHESION TO NORMAL AND
DIS PLASTIC COLONIC MUCOSA BY AN EX-VIVO ORGAN CULTURE
EXPERIMENTAL MODEL
Pagnini Cristiano*[1], Corleto Vito[1], Di Giulio Emilio[1], Delle Fave Gianfranco[1]
[1]
Universita' di Roma "La Sapienza" - Roma, Italy
15A ul a c T ue s day, S e pt e m be r 1 3
OC 2.4 - LACTOBACILLUS CASEI RHAMNOSUS STRAIN GG INHIBITS THE
OXIDATIVE STRESS INDUCED BY ROTAVIRUS IN HUMAN ENTEROCYTES
Buccigrossi Vittoria*[1], Laudiero Gabriella[1], Sofia Morena[1], Oliva Valentina[1], Verrone
Maria Antonietta[1], Wudy Anna[1], Guarino Alfredo[1]
[1]
Dept. of Pediatrics University of Naples "Federico II°" - Naples, Italy
OC 2.5 - MOLECULAR BIOLOGICAL METHODS FOR RAPID DETERMINATION
OF LACTIC ACID BACTERIA STRAINS ISOLATED FROM FOOD AND
ENVIRONMENTAL SAMPLES
Szen Orsolya*[3], Pal Karoly[4], Naar Zoltan[4], Kiss Attila[5]
[3]
Egerfood National Knowledge Centre - Eszterhazy Karoly College - Eger, Hungary -
[4]
Eszterhazy Karoly College - Dept. of Microbiology and Food Technology - Eger, Hungary -
[5]
Eszterhazy Karoly College - Dept. of Food Chemistry and Biochemistry - Eger, Hungary
OC 2.6 - PROBIOTIC STRUCTURE FUNCTION ANALYSIS REVEALS PRTP-
ENCODED LACTOCEPIN TO MEDIATE ANTI-INFLAMMATORY EFFECTS VIA
SELECTIVE DEGRADATION OF IP-10
Szen Orsolya*[3], Pal Karoly[4], Naar Hörmannsperger Gabriele*[1], von Schillde Marie-
Anne[1], Weiher Monika[1], Alpert Carl-Alfred[2], Hahne Hannes[3], Bäuerl Christine[4],
Perez Gaspar[4], Haller Dirk[1]
Biofunctionality, Technical University of Munich - Freising-Weihenstephan, Germany -
[1]
[2]Gastrointestinal microbiology, German Institute for Human Nutrition - Potsdam-Rehbrücke,
Germany - [3]Chair for Bioanalytics, Technical University of Munich - Freising-Weihenstephan,
Germany - [4]Departamento de Biotecnología, Instituto de Agroquímica y Tecnología de
Alimentos - Valencia, Spain
OC 2.7 - PROTECTION AGAINST SEPSIS BY PROBIOTIC THERAPY IS
CORRELATED WITH STIMULATION OF A NOT PREVIOUSLY DESCRIBED
BACTERIAL PHYLOTYPE
Gerritsen Jacoline*[1], Timmerman Harro M.[2], Fuentes Susana[1], van Minnen L. Paul[2],
Panneman Henk[3], Konstantinov Sergey R.[1], Rombouts Frans M.[1], Gooszen Hein
G.[2], Akkermans Louis M. A.[2], Smidt Hauke[1], Rijkers Ger T.[2]
Wageningen University - Wageningen, Netherlands - [2]University Medical Center - Utrecht,
[1]
Netherlands - [3]Dr. van Haeringen Laboratorium B.V. - Wageningen, Netherlands
OC 2.8 - EFFECT OF A NOVEL TRANS-GALACTOOLIGOSACCHARIDE MIXTURE
(B-GOS) ON METABOLIC SYNDROME RISK FACTORS IN OVERWEIGHT
ADULTS
Vulevic Jelena*[1], Juric Aleksandra[2], Tzortzis George[2], Gibson Glenn[3]
University of Reading/Clasado Ltd. - Reading, United Kingdom - [2]Clasado Ltd. - Reading,
[1]
United Kingdom - [3]University of Reading - Reading, United Kingdom
OC 2.9 - EFFECTS OF ANTIBIOTIC THERAPY ON THE GASTROINTESTINAL
MICROBIOTA AND THE INTERVENTION WITH L.CASEI
Angelika Pirker[1], Berit Hippe[1], Christoph Kamhuber[2], Felix Stockenhuber[2],
Alexander Haslberger*[1]
Univ. Vienna, Dep for Nutritional Sciences - Vienna, Austria - [2]Krankenhaus Oberpullendorf, -
[1]
Vienna, Austria
16T ue sday, Se p t e mbe r 1 3 Aul a c
OC 2.10 - GLYCOSAMINOGLYCANS OF HUMAN MILK DURING THE FIRST MONTH
OF LACTATION: FURTHER POTENTIAL PREBIOTICS FOR THE BREASTFED INFANT
Coppa Giovanni Valentino*[1], Gabrielli Orazio[1], Zampini Lucia[1], Galeazzi Tiziana[1],
Padella Lucia[1], Bertino, Enrico[2], Maccari Francesca[3], Volpi Nicola[3]
[1]
Università Politecnica Marche - Ancona, Italy - [2]
Università di Torino - Torino, Italy -
[3]
Università Modena e Reggio Emilia - Modena, Italy
OC 2.11 - L. PLANTARUM TENSIA COMPRISING PROBIOTIC CHEESE WITH
HYPOTENSIVE EFFECT
Hütt Pirje*[1], Songisepp Epp[2], Rätsep Merle[2], Shkut Elena[2], Zilmer Mihkel [3], Ehrlich
Kersti[3], Mikelsaar Marika [1]
University of Tartu, Dept. of Microbiology - Tartu, Estonia - [2]Bio-Competence Centre of
[1]
Healthy Dairy Products LLC - Tartu, Estonia - [3]University of Tartu, Dept. of Biochemistry -
Tartu, Estonia
OC 2.12 - STUDY OF PROBIOTIC WHEY BASED ORAL REHYDRATING
SOLUTION (BIO-ORS) AGAINST SHIGELLA DYSENTERIAE INFECTION IN MICE
Goyal Nupur*[1]
[1]
Amity Institute of Biotechnology,Amity University - Noida, India
OC 2.13 - THERAPEUTIC EFFECTS OF OAT AND MILK BASED PROBIOTIC
FERMENTED PRODUCT AGAINST TYPE 2 DIABETES
Sangwan Seema*[1], Karasi Anbu K[1], Nanda Dhiraj K[2], Poply Sarang[1], Singh
Rameshwar[1]
[1]
National Dairy Research Institute - Karnal, India - [2]
National Bureau of Animal Genetic
Resources - Karnal, India
OC 2.14 - TANAGEL REDUCE COLITIS SEVERITY IN DEXTRAN SODIUM
SULPHATE (DSS) MODEL OF MURINE ACUTE COLITIS
Lopetuso Loris Riccardo*[1], Scaldaferri Franco[1], Cufino Valerio[2], Petito Valentina[2],
Gerardi Viviana[1], Pizzoferrato Marco[1], Pecere Silvia[1], Laterza Lucrezia[1], Stigliano
Egidio[2], Arena Vincenzo[2], Sgambato Alessandro[2], Gasbarrini Antonio[1]
Internal Medicine, CATHOLIC UNIVERSITY OF ROME - Roma, Italy - [2]Pathology, CATHOLIC
[1]
UNIVERSITY OF ROME - Roma, Italy
OC 2.15 - MODULATION OF THE FAECAL MICROBIOTA PROFILE AND IMMUNE
MARKERS BY A NOVEL TRANS-GALACOOLIGOSACCHARIDE MIXTURE (B-GOS)
IN OVERWEIGHT ADULTS
Vulevic Jelena*[1], Juric Aleksandra[3], Tzortzis George[2], Gibson Glenn[4]
University of Reading/Clasado Ltd. - Reading, United Kingdom - [2]Clasado Ltd. - Reading,
[1]
United Kingdom - [3]Clasado Ltd. - Reading, United Kingdom - [4]University of Reading - Reading,
United Kingdom
OC 2.16 - OBESITY-INDUCED CHANGES IN GUT MICROBIOTA ARE GENERATED
BY MUCOSAL DEFENSINS AND MODULATED BY LACTOBACILLUS CRISPATUS
M247 DIET SUPPLEMENTATION
Cavallo Donatella[1], Elli Marina[2], Morelli Lorenzo[3], Moratelli Ketty[1], Castagliuolo
Ignazio[1], Martines Diego[1], Brun Paola*[1]
Università di Padova - Padova, Italy -
[1] [2]
AAT - Piacenza, taly - [3]
Cattolic University -
Piacenza, Italy
17A ul a c T ue s day, S e pt e m be r 1 3
OC 2.17 - ADMINISTRATION OF BERBERINE IMPROVES HEPATIC NECRO-
INFLAMMATION IN MURINE STEATOHEPATITIS, BUT IS ASSOCIATED WITH
INCREASED MORTALITY
Elisa Vivoli[1], Angela Provenzano[1], Stefania Madiai[1], Erica Novo[1], Maurizio Parola[1],
Fabio Marra [1]
[1]
University of Florence - Florence, Italy
OC 2.18 - FACTORS INFLUENCING CLINICAL EFFICACY OF VAGINAL PROBIOTICS
Heczko Piotr*[1], Strus Magdalena[1], Wiecek Grazyna[1], Kupka Anna[1],
Kryczyk Jadwiga[1]
[1]
Jagiellonian University Medical College - Krakow, Poland
OC 2.19 - PROBIOTIC VSL#3 MAY BE EFFECTIVE TO CHANGE THE PROFILE
OF CYTOCHINES AND IMMUNOGLOBULINS IN BREAST MILK ?
Baldassarre Mariella*[1], Fanelli Margherita[2], Tafaro Angela[3], Laforgia Nicola[1]
Ospedale Policlinico-Neonatology and NICU, University of Bari - Bari, Italy - [2]Dept of Internal
[1]
Medicin and Public Health, Section of Diagnostic Imaging, Medical Statistics, University of Bari
- Bari, Italy - [3]IRCCS Ospedale "S.De Bellis" - Castellana Grotte, Italy
OC 2.20 - EFFECT OF DIETARY SUPPLEMENTATION OF A LACTOBACILLUS
PLANTARUM STRAIN IN AN ARTIFICIALLY INDUCED NECROTIZING
ENTEROCOLITIS MODEL
Castro Erica*[1], Jofre Jaime[1], Vera Rodrigo[1], Monsalvez Elizabeth[1], Pardo Karen[1],
Aguayo Maria[1], Soza Francisco[1], Stillfried Nicolas[1], Medina Rossi[1], Labra Alan[1],
Montecinos Hernan[1]
[1]
Universidad De Concepciòn - Concepciòn, Chile
18T ue sd ay, S ep t e m be r 13 A ul a NE W MAN
08.30 - 10.30 a.m. DERMATOLOGY SESSION
Chairman: M. Picardo (Italy)
Nutrition and skin
M. Picardo (Italy)
Probiotics and atopic dermatitis
V. Fabiano (Italy)
Probiotics and seborrheic dermatitis
C. Vincenzi (Italy)
Dietary antioxidants and photoprotection
E. Camera (Italy)
Antioxidants and skin diseases
M. Picardo (Italy)
Nutraceuticals for hair and nails
B.M. Piraccini (Italy)
Effects of Lactobacillus salivarius Ls01 (DSM 22775) treatment on atopic
dermatitis in adults: randomized placebo-controlled study
L. Drago (Italy)
10.30 - 11.15 a.m. LECTURES
Chairman: G. Scapagnini (Italy)
The use of carnitine in patients with elevated levels of Lp(a)
C. Sirtori (Italy)
The role of meta-analysis in the evaluation of probiotics: arguments for and against
H. Szajewska (Poland)
11.15 a.m.- 12.30 p.m. PROBIOTICS IN FOODS
Chairpeople: P. Aureli (Italy), G.L. Gianfranceschi (Italy)
Role of the probiotic strain Lactobacillus paracasei LMGP22043 carried by artichokes
in influencing faecal bacteria and biochemical parameters in human subjects
P. Lavermicocca (Italy)
Use of Lactobacillus paracasei enriched artichokes in the treatment of functional
constipation
G. Riezzo (Italy)
Effects of a diet with inulin-enriched pasta on intestinal permeability in healthy
young volunteers
F. Russo (Italy)
Antiproliferative effects of LGG and L. paracasei on HGC-27 and DLD-1 human
gastrointestinal cell lines
A. Orlando (Italy)
Lactotripeptides from L. helveticum and blood pressure modulation
A.F.G. Cicero (Italy)
Dysbiosis, probiotics and IBS
R. Francavilla (Italy)
19p os t e r s
P1 INTERFENCES OF A SYMBIOTIC FORMULATION ON A GASTRIC AND INTESTINAL PERMEABILITY
IN RATS WITH EXPERIMENTALLY INDUCED CHRONIC LIVER DAMAGE
Cariello Rita[1], Tuccillo Concetta[1], Mazzone Giovanna[2], Ribecco Maria Teresa[2], Federico Alessandro[1],
Iadevaia Maddalena[1], De Magistris Laura[1], D'Argenio Giuseppe*[2], Grossi Enzo[3], Caporaso Nicola[2],
Loguercio Carmela[1]
Dipartimento Medico-Chirurgico di Internistica Clinica e Sperimentale, SUN - Napoli, Italy - [2]Dipartimento di Medicina
[1]
Clinica e Sperimentale, Univ. Federico II - Napoli, Italy - [3]Bracco Spa, Italy
P2 EVALUATION AND GENETIC VALIDATION OF MEDIA SELECTIVE FOR BIFIDOBACTERIUM
Rebecchi Annalisa*[1], Pisacane Vincenza[1], Callegari Maria L.[1], Morelli Lorenzo[1]
[1]
Centro Ricerche Biotecnologiche- Università Cattolica del Sacro Cuore - Cremona, Italy
P3 IN VITRO PROBIOTIC EVALUATION USING A MICROBIAL ENGINEERING APPROACH WITH THE
3S-ECSIM, A 3-STAGES ENVIRONMENTAL CONTROL SYSTEM FOR INTESTINAL MICROBIOTA
David Féria-Gervasio[1], William Tottey*[1], Pascal Vandekerckove[2], Monique Alric[1], Jean-François Brugère[1]
[1]
ERT-CIDAM - Clermont-Ferrand, France - [2]Lesaffre International Sarl - Marcq En Baroeul, France
P4 INVESTIGATION OF ANTIBACTERIAL ACTIVITY OF LACTOBACILLUS SPECIES
Szen Orsolya*[1], Pal Karoly[2], Hilyakne Kadlott Maria[2], Naar Zoltan[2], Kiss Attila[3]
Egerfood National Knowledge Centre - Eszterhazy Karoly College - Eger, Hungary - [2]Eszterhazy Karoly College -
[1]
Dept. of Microbiology and Food Technology - Eger, Hungary - [3]Eszterhazy Karoly College - Dept. of Food Chemistry
and Biochemistry - Eger, Hungary
P5 LACTOBACILLUS PLANTARUM TENSIA AND LACOBACILLUS PLANTARUM INDUCES
ANTILISTERIAL ACTIVITY IN EXPERIMENTAL CHEESE
Rätsep Merle*[1], Smidt Imbi [2], Songisepp Epp [1]
[1]
Bio-Competence Centre of Healthy Dairy Products LLC - Tartu, Estonia - [2]University of Tartu - Tartu, Estonia
P6 LACTOBACILLUS REUTERI IMPROVES THE ERADICATION RATE OF HELICOBACTER PYLORI
Efrati Cesare*[1], Nicolini Giorgia[1], Cannaviello Claudio[1]
[1]
Ospedale israelitico - Roma, Italy
P7 LACTOBACILLUS RHAMNOSUS LR06 DSM 21981, LACTOBACILLUS PENTOSUS LPS01 DSM
21980, LACTOBACILLUS PLANTARUM LP01 LMG P-21021 AND LACTOBACILLUS DELBRUECKII
SUBSP. DELBRUECKII LDD01 DSM 22106 IN VITRO STRONGLY INHIBIT DIFFERENT
ESCHERICHIA COLI SEROTYPES, INCLUDED E. COLI O157:H7
M. Del Piano *[1], G.P. Strozzi[2], F. Deidda[3], S. Allesina[3], M. Barba[3], L. Soattini[4], F. Sforza[4], G. Mogna[2]
Gastroenterology Independent Operating Unit, Maggiore della Carità Hospital - Novara, Italy - [2]Probiotical SpA -
[1]
Novara, Italy - [3]Biolab Research Srl - Novara, Italy - [4]Casa di Cura I Cedri - Novara, Italy
P8 PROBIOTICS FOR PREVENTION OF NECROTIZING ENTEROCOLITIS IN PRETERM INFANTS
Al Faleh Khaled*[1], Anabrees Jasim[1], Bassler D[2], Al-Kharfi T[1]
[1]
King Saud University - Riyadh, Saudi Arabia - [2]U - Germany
P9 QUANTIFICATION OF LACTIC ACID AND ENTERIC BACTERIA BY MEANS OF QPCR
Pal Karoly*[1], Szen Orsolya[2], Naar Zoltan[1], Kiss Attila[3]
Eszterhazy Karoly College, Dept. of Microbiology and Food Technology - Eger, Hungary - [2]Eszterhazy Karoly College,
[1]
EGERFOOD Regional Knowledge Centre - Eger, Hungary - [3]Eszterhazy Karoly College, Dept. of Food Chemistry and
Biochemistry - Eger, Hungary
20p os t e r s
P10 THE USE OF LACTOBACILLUS GG IN CHILDREN WITH FUNCTIONAL ABDOMINAL PAIN: A
DOUBLE-BLIND RANDOMIZED CONTROL TRIAL
Sabbi Tamara*[1], Palumbo Massimo[1]
[1]
Belcolle Hospital Viterbo - Pediatric Unit, Italy
P11 IN VITRO EFFECT OF FOUR NOVEL FLOURS FERMENTATION ON GUT MICROBIOTA PARAMETERS
Chitarrari Roberto*[1], Carnevali Paola[2], Costabile Adele[1]
Food Microbial Sciences, School of Food and Nutritional Sciences, University of Reading - Reading, United Kingdom
[1]
- Barilla G. e R. Fratelli - Parma, Italy
[2]
P12 SURVIVAL OF LACTOBACILLUS RHAMNOSUS LR06 DSM 21981, LACTOBACILLUS PENTOSUS
LPS01 DSM 21980, LACTOBACILLUS PLANTARUM LP01 LMG P-21021 AND LACTOBACILLUS
DELBRUECKII SUBSP. DELBRUECKII LDD01 DSM 22106 IN DIFFERENT PARTS OF THE
DIGESTIVE TRACT OF PATIENTS CHRONICALLY TREATED WITH PPI
M. Del Piano *[1], M. Ballarè[1], M. Pagliarulo[1], A. Anderloni[1], M. Balzarini[1], M. Orsello[1], S. Carmagnola[1],
R. Tari[1], F. Deidda[3], S. Allesina[3], M. Barba[3], G.P. Strozzi[2], G. Mogna[2],
L. Mogna[2], F. Sforza[4]
Gastroenterology Independent Operating Unit, Maggiore della Carità Hospital, Novara - Italy - [2]Probiotical SpA,
[1]
Novara, Italy - [3]Biolab Research Srl - Novara, Italy - [4]Casa di Cura I Cedri - Novara, Italy
P13 STRUCTURAL CHARACTERIZATION OF CHONDROITIN SULFATE FROM ITALIAN CHEESE
PARMIGIANO REGGIANO
Coppa Giovanni[1], Maccari Francesca[2], Zampini Lucia[1], Santoro Lucia[1], Galeazzi Tiziana[1], Gabrielli
Orazio[1], Volpi Nicola*[2]
Polytechnic University of the Marche, Ospedali Riuniti, Presidio Salesi - Ancona, Italy - [2]University of Modena and
[1]
Reggio Emilia - Modena, Italy
P14 FLAVONOIDES AND GASTROINTESTINAL TRACT: FROM THE BENCH TO CLINICAL PERSPECTIVES
Marotta Francesco*[1], Tomella Claudio[1], Polimeni Ascanio[1], Joyal Steven[2]
[1]
ReGenera Res Group - Milano, Italy - [2]Life Extension Foundation - Ft. Lauderdale, USA
P15 SUPPLEMENTATION WITH LACTOBACILLUS HELVETICUS AND BIDIFOBACTERIUM LONGUM
INDUCED IMMUNOLOGICAL CHANGES IN MODERATE MALNOURISHED ELDERLY SUBJECTS
Finamore Alberto*[1], Roselli Marianna[1], Brasili Elisa[1], Donini Lorenzo M [2]
, Neri Barbara [3]
, Carnevali
Paola [4], Mengheri Elena[1]
[1]
National Research Institute on Food and Nutrition (INRAN) - Roma, Italy - [2]Sapienza University - Rome, Italy -
[3]
Villa delle Querce Rehabilitation Institute - Nemi, Italy - [4]Barilla G. e R. Fratelli - Parma, Italy
P16 CAN LACTOBACILLUS RHAMNOSUS LR06 DSM 21981, LACTOBACILLUS PENTOSUS LPS01
DSM 21980, LACTOBACILLUS PLANTARUM LP01 LMG P-21021 AND LACTOBACILLUS
DELBRUECKII SUBSP. DELBRUECKII LDD01 DSM 22106 RESTORE THE “GASTRIC BARRIER
EFFECT” IN PATIENTS CHRONICALLY TREATED WITH PPI?
M. Del Piano*[1], M. Ballarè[1], M. Pagliarulo[1], A. Anderloni[1], M. Balzarini[1], M. Orsello[1], S. Carmagnola[1],
R. Tari[1], F. Deidda[3], S. Allesina[3], M. Barba[3], G.P.Strozzi[2], G. Mogna[2], L. Mogna[2], F. Sforza[4]
Gastroenterology Independent Operating Unit, Maggiore della Carità Hospital, Novara, Italy -
[1] [2]
Probiotical SpA,
Novara, Italy - [3]Biolab Research Srl, Novara, Italy - [4]Casa di Cura I Cedri, Novara, Italy
P17 CHARACTERISATION OF THE CYANOBACTERIAL TOXIN REMOVAL PROCESS IN THE PRESENCE
OF PROBIOTIC BACTERIA
Nybom Sonja*[1], Dziga Dariusz[2], Salminen Seppo[3], Meriluoto Jussi[1]
[1]
Åbo Akademi University/Department of Biosciences - Turku, Finland - [2]Jagiellonian University - Krakow, Poland -
[3]
University of Turku - Turku, Finland
21p os t e r s
P18 PROBIOTIC LACTOBACILLUS RHAMNOSUS LGA UPREGULATES ß-DEFENSIN AND EXPRESSION
IN CULTURED CHICKEN SMALL INTESTINAL EPITHELIAL CELLS
Guanhong Li*, Siguo Liu, Zhimin Hong, Yongjie Jia, Jinming You, Minreng Qu Minreng[1]
College of Animal Science and Technology, Jiangxi Agricultural University - Nanchang, China - [2]Harbin Veterinary
[1]
Research Institute of Chinese Academy of Agricultural Sciences - Harbin, China
P19 SELENIUM AND ZINC INTERNALIZED BY LACTOBACILLUS BUCHNERI LB26 DSM 16341 AND
BIFIDOBACTERIUM LACTIS BB1 DSM 17850: DEVELOPMENT OF A NEW BIOLOGICAL METHOD
TO EVALUATE THE BIOAVAILABILITY OF THE TWO MINERALS
M. Pane*[2], M. D'Andrea[3], S. Nicola[3], G.P. Strozzi[2], G. Mogna[2], M. Del Piano [1]
Gastroenterology Independent Operating Unit, Maggiore della Carità Hospital - Novara, Italy - [2]Probiotical SpA -
[1]
Novara, Italy - [3]Biolab Research Srl - Novara, Italy
P20 SAFETY OF A PROBIOTIC CHEESE COMPRISING L. PLANTARUM TENSIA ACCORDING VARIETY
OF HEALTH INDICES IN DIFFERENT AGE GROUPS
Songisepp Epp*[1], Hütt Pirje [2], Rätsep Merle [1], Shkut Elena [1], Zilmer Mihkel [2], Kõljalg Siiri[2], Truusalu
Kai[2], Smidt Imbi[2], Kolk Helgi[2], Zagura Maksim [3], Mikelsaar Marika [2]
[1]
Bio-Competence Centre of Healthy Dairy Products LLC - Tartu, Estonia - [2]University of Tartu - Tartu, Estonia -
[3]
Tartu University Clinics - Tartu, Estonia
P21 EFFECT OF LAB ON CYTOKINE SECRETION BY THP-1 CELLS STIMULATED BY LPS
Hacin Biljana*[2], Citar Manuela[2], Tompa Gorazd[1], Rogelj Irena[1]
[1]
University of Ljubljana - Ljubljana, Slovenia - [2]Medis, d.o.o., Ljubljana, Slovenia
P22 SLOWL RELEASE EFFERVESCENT TABLETS WITH L. FERMENTUM LF10 DSM 19187 AND L.
ACIDOPHILUS LA02 DSM 21717 INHIBIT CANDIDA AND PUTRESCENT FLORA
G. Mogna[1], F. Deidda[2], S. Allesina[2], M. Pane[2], M. Barba[2], M. D’Andrea[2], P. Lorenzini[2], S. Nicola[2],
E. Raiteri[2], G.P. Strozzi[1], L. Mogna[2], F. Vicariotto[3]
Probiotical SpA - Novara, Italy -
[1]
Biolab Research Srl - Novara, Italy [3] - Department of Obstetrics and Gynecology,
[2]
San Pio X Hospital - Milan, Italy
P23 SYMPTOM RESOLUTION AND IMMUNE MATURATION IN INFANTS WITH ATOPIC DERMATITIS
RECEIVING HYDROLYZED FORMULA WITH LACTOBACILLUS GG (LGG)
Nermes Merja[1], Salminen Seppo[1], Isolauri Erika*[1]
[1]
University of Turku - Turku, Finland
P24 THE GLOBAL PHENOTYPIC ANALYSIS OF PUTATIVE ANTIALLERGIC POTENTIAL OF THREE
LACTOBACILLUS STRAINS
Aleksandrzak-Piekarczyk Tamara*[1], Koryszewska-Baginska Anna[1], Bardowski Jacek[1]
[1]
Institute of Biochemistry and Biophysics Polish Academy of Sciences - Warsaw, Poland
P25 IS CRANBERRY USEFUL FOR PREVENTION RECURRENT URINARY TRACT INFECTIONS IN
CHILDREN?
Dessì Angelica*[1], Fanos Vassilios[1]
Department of Paediatrics, Neonatal Intensive Care Unit, Neonatal Pathology, Puericultura Institute and Neonatal
[1]
Section, University of Cagliari - Cagliari, Italy
22p os t er s
P26 LACTOBACILLUS SPP. STRAINS OF CULTURE COLLECTION OF TARTU UNIVERSITY, ESTONIA
Štšepetova Jelena*[1], Rööp Tiiu[1], Mändar Reet[1], Sepp Epp[1], Mikelsaar Marika[1]
[1]
University of Tartu - Tartu, Estonia
P27 ASSESSMENT OF SAFETY AND TOLERANCE OF A FERMENTED DAIRY FOOD CONTAINING
NOVEL, POTENTIALLY PROBIOTIC STRAINS
Chambaud Isabelle*[1], Jeansen Stéphanie[1], Elfakir Anissa[1], Banning Federike[2], Queudot
Jean- Christophe[3], Bouchez Elodie[3], Bourlioux Pierre[4], Marteau Philippe[5], Schrezenmeir Juerguen[6]
Danone Research - Palaiseau, France - [2]Harrison Clinical Research Deutschland GmbH - Munich, Germany - [3]CIT
[1]
Safety and Health Research Laboratories - Evreux, France - [4]Faculty of Parmacy - Paris-Sud University - Paris, France
- [5]University Denis Diderot, Paris 7 & AP-HP, Lariboisière ospital - Paris, France - [6]Gutenberg-University Mainz -
Kiel, Germany
P28 PROBIOTIC TREATMENT INDUCED AGE DEPENDENT METABOLIC CHANGES
Brasili Elisa[1], Tomassini Alberta [2], Finamore Alberto*[1], Roselli Marianna [1], Mengheri Elena[1], Capuani
Giorgio[2], Sciubba Fabio[2], Miccheli Alfredo[2]
[1]
National Research Institute on Food and Nutrition, INRAN - Roma, Italy - [2]Sapienza University - Roma, Italy
P29 COMPARATIVE STUDY ON THE CELL SURFACE PROPERTIES AND STRUCTURE OF
EXOPOLYSACCHARIDES PRODUCED BY LACTOBACILLUS CASEI AND LACTOBACILLUS
PARACASEI STRAINS
Górska-Fraczek Sabina*[1], Gamian Andrzej[1], Kozakova Hana[2], Schwarzer Martin[2]
[1]
Institute of Immunology and Experimental Therapy, Polish Academy of Sciences, - Wroclaw, Poland - [2] Department
of Immunology and Gnotobiology, Institute of Microbiology of the Academy of Sciences of the Czech Republic, v. v.
i - Novy Hradek, Czech Republic
P30 PREBIOTIC AND ANTIMICROBIAL EFFECT OF KEFIRAN
Vardjan Tinkara*[1], Canžek Majhenic Andreja[2], Rogelj Irena[2]
[1]
Kele & Kele, d.o.o. - Logatec, Slovenia - [2]University of Ljubljana, Biotechnical Faculty - Domžale, Slovenia
23September 2013
7 probiotics &prebiotics
th
new foods
ROMEABSTRACTS
OR AL C OMM UNI C AT ION S 1
OC1.1 shown to negatively influence the composition and
PATHOGEN AND PROBIOTIC BACTERIA DIFFERENTIALLY functionality of our intestinal microbiota. The most prominent
STIMULATE NITRIC OXIDE PRODUCTION AND S100B sign of this is antibiotic associated diarrhoea, but it can also
PROTEIN EXPRESSION IN HUMAN ENTEROGLIAL CELLS manifest itself in more benign side effects as bloating, gas,
Turco Fabio*[2], Sarnelli Giovanni[2], Cirillo Carla[3], Mango cramps, etc. Probiotics have in several studies shown to
Annamaria[2], Nasti Anna[2], D'Alessandro Alessandra[2], ameliorate the risk for antibiotic associated diarrhoea (AAD);
Farina Virginia[2], Cuomo Rosario[2] in particular Saccharomyces cerevisiae (boulardii), but also
Università Federico II - Napoli, Italy - [3]K.U. Leuven - Leuven, Belgium
[2] various strains of lactobacillus probiotics. We have recently
shown that a combination of lactobacilli and bifidobacteria
Background and aim: Enteric glial cells (EGC) are involved in was able to maintain the stability of the whole microbiota of
intestinal homeostasis and may contribute to regulate host- volunteers consuming antibiotics. We therefore aimed to
bacteria interaction. Astrocytes, the equivalent of enteroglial investigate the effect of this probiotic combination on patients
cells (EGC) in Central Nervous System respond to bacteria seeking clinical care and being prescribed antibiotics. We
releasing nitric oxide (NO), whether this occur in bacterial-EGC recruited 503 patients whom were randomised over three
interaction and whether glial derived S100B protein is involved groups receiving either a placebo (micro crystalline cellulose)
in this response is not known. We aimed to investigate the or a combination of L. paracasei Lpc-37, L. acidophilus
effects of pathogens and probiotics on NO release from EGC. NCFM, B. lactis Bi-07 and B. lactis Bl-04 at a dose of 2.5 x
Material and methods: Human EGC were obtained according 109 CFU/day (Low) or 1010 CFU/day (High). Incidence and
to a method previously described by our group. Briefly, duration of diarrhoea was assessed as well as the incidence
myenteric plexus preparations were isolated from ileum of of Clostridium difficile associated diarrhoea Subjects were
patients undergoing surgery and enzimatically dissociated. 50 years of age (±11 years). Older subjects were more likely
Ganglia were plated and cell cultures were grown to to suffer from AAD then younger subjects; also subjects with
subconfluence. After 21 days, EGC were purified by incubation a longer exposure to antibiotics were more likely to suffer
with the anti-Thy-1.1 ab-coated magnetic beads and separated from AAD. Women tended to have a higher incidence of AAD,
using a Dynal Magnet®. EGC were incubated for 24 hours with but this did not reach statistical significance. Over all
the probiotic Lactobacillus Paracasei F19 (LP F19) and the incidence of AAD was 19% while overall incidence of C.
pathogen Enteroinvasive Escherichia Coli (EIEC). 2 different difficile associated diarrhoea (CDAD) was 2.8%. There was
bacteria/cells ratios were used (0.1/1 and 10/1, respectively). a significant difference in the incidence of AAD between the
Nitrite assay and Western Blot analysis were respectively used treatment groups; 25%, 20% and 13%, for placebo, Low and
to evaluate NO release and S100B expression in stimulated High dose, respectively. There was also a significant
cells compared to unstimulated cells that served as controls. difference in CDAD between the treatment groups; 4.8%,
Data are expressed as mean±SD of 3 independent 1.8% and 1.8%, for placebo, Low and High dose,
experiments. Results: Glial derived S100B protein expression respectively. Also the duration of diarrhoea was significantly
was significantly higher in response to EIEC than to LP F19 different between groups; 5.4, 2.6 and 3.5 days (placebo,
(+2.9±0.2 and +0.9±0.3 fold increase vs control; pOR AL COM MU NIC AT I ONS 1 biological and morphological SMC features whereas that of strategies using probiotics have been considered. TLR2 by LGG reduces LPS-induced effects. AIMS: to analyze Complementary in vitro approaches have been used to better cellular mechanisms involved in LGG protective role against understand the behavior of EHEC in the human digestive LPS-induced motor alterations. METHODS: The direct effect environment and investigate the antagonist properties of of 120x106CFU/ml LGG (ATCC 53103 strain) was tested on Saccharomyces cerevisiae CNCM I-3856 probiotic strain. a highly pure human SMC culture exposed to the TLR4 AIMS & methods: First, in vitro digestions of a standard meal agonist LPS (1µg/ml) for 24h. LGG effects were evaluated on containing ground beef inoculated with EHEC O157:H7 or EHEC LPS-induced NFkB activation, cytokines production and with S. cerevisiae were performed in a dynamic gastro-intestinal muscular morphofunctional properties. NFkB activation was tract model (TIM). Second, we analyzed the ability of EHEC examined by ELISA determination of the phosphorylation of O157:H7 (i) to interact in vivo with murine Peyer’s Patches (PPs) p65 NFkB subunits Ser468 and Ser536. Cytokines production in ileal loop assay and ex vivo in Ussing chambers and (ii) to was determined by ELISA for the pro-inflammatory IL6 and translocate in vitro using an M cell model. RESULTS: Bacterial the anti-inflammatory IL10. Data are expressed as mean±SD, mortality was observed in the stomach and duodenum of the p
OR AL C OMM UNI C AT ION S 1
or 7 days was reduced by 35% (CI 99% 0.33-1.29) and by the investigation of effects of probiotic intervention on fecal
46% (0.21-1.30), respectively, following Bl-04 intake. microbiota in antibiotic induced diarrhea, suggests quite
Incidence of lower respiratory tract infections lasting 5 days striking changes in the abundance of subgroups of
or more was reduced by 45% (0.24-1.27). In line with the microbiota. Therefore, changes of subgroups of GI-
clinical effects, the medication use during infections lasting microbiota as well as intervention with different probiotic
5 days or more was reduced by 45% (0.30-0.99). Illness total strains should discriminate effects of bacteria on immune-
load (severity x duration) was 27% (0.45-1.18) lower in or endothelial cells.
subjects taking B. lactis Bl-04 than those on the placebo. No
substantial effects of supplementation were evident on OC1.7
gastrointestinal illness between the probiotic and placebo SUPPLEMENTATION OF YOGURT BY COMMERCIALLY
groups. The data from this study indicate that B. lactis BI-04 AVAILABLE BACILLUS CLAUSII ENDOSPORES
has beneficial clinical effects in healthy physically active Pal Karoly*[1], Szarvas Jozsef[4], Hilyakne Kadlott Maria[1],
individuals. Other researchers report that healthy individuals Szen Orsolya[5], Naar Zoltan[1], Kiss Attila[4]
want an on average 25% to 57% reduction in common cold [1]
Eszterhazy Karoly College, Dept. of Microbiology and Food Technology
illness severity to justify costs of treatments. Therefore, B. - Eger, Hungary - [4]Eszterhazy Karoly College, Dept. of Food Chemistry
lactis Bl-04 supplementation in this study achieved a and Biochemistry - Eger, Hungary - [5]Eszterhazy Karoly College,
sufficiently important difference in the reduction of upper EGERFOOD Regional Knowledge Centre - Eger, Hungary
respiratory tract illness to meet this criterion. Furthermore,
the findings of this study indicate that prophylactic use of Development of probiotic products is based on the use of
this supplement could substantially reduce the economic microbes having numerous beneficial effects on the human
cost of the common cold. health. Majority of probiotic organisms belong to the group
of lactic acid bacteria, but rarely other microbes are shown
OC1.6 to have probiotic effects, too. The endospore forming B.
HEAT INACTIVATED PROBIOTIC STRAINS SPECIFICALLY clausii is one of these exceptions and its endospores are used
STIMULATE NFK-, MAP KINASE PATHWAYS, DIFFERENT in a commercially available product. Since no literature was
MIRNAS AND MATURATION IN CACO II ENDOTHELIAL CELLS found about the use of B. clausii in food, we investigated the
AND IN DENDRITIC CELLS survival of endospores and their impact on the starter culture
Ladan Giahi[1], Eva Aumueller[1], Manuela Nestlberger[1], and ripening process of yogurt. We used fresh, warm (42 °C)
Ibrahim Elmadfa[1], Alexander Haslberger*[1] yogurt samples that were inoculated by the starter cultures
Univ Vienna, Dep. Nutritional Sciences - Vienna, Austria
[1]
(Lactobacillus delbrueckii ssp. bulgaricus and Streptococcus
thermophilus) 30 minutes before the experiment. Spore
Introduction: Probiotic strains have been shown to activate number of the B. clausii suspension was counted prior to
cell responses involving toll like receptors (TLRs) and NF-kb addition; 175 g yogurt was inoculated by 109 cfu of spores.
pathways. Objectives and methods: We investigated effects After inoculation the yogurt cups were closed and treated the
of heat inactivated Lactobacillus, Bifido- and Streptococcus same way as in the normal manufacturing procedure. Two
strains on expression of inflammatory mediators, maturation parameters of acidity, the Soxhlet-Henkel degree (°SH) and
markers, NF-kb and miRNAs in the endothelial CACO II cell pH were measured during the 4 hours of ripening in every
line and in dendritic cells derived from whole blood. hour. The yogurts were stored at 4 °C for 16 days; endospore
Expression of immune- and inflammatory mediators, kbs and and total cell numbers were counted regularly. At the end of
miRNAs were analysed by qRT-PCR. MiRU6 was used as a the experiment the yogurts were tasted and scored. Our
control. Maturation markers of dendritic cells were results showed that addition of B. clausii endospores did not
determined with FACS-analysis. Results: In untreated or have any significant effect on the progress of ripening. Acidity
IL1ß- pretreated CACO2 cells the expression of IL6 and TNFa was not altered, pH and °SH in the supplemented yogurts
as well as NF?Bp65 and Ikb as well as p38 was increased changed in the same rate and degree as in the control
differently after treatment with heat inactivated cells of samples. B. clausii endospores survived the ripening and
Lactobacillus acidophilus, Streptococcus thermophilus and storage period very well. Taste, texture, colour and smell of
Bifidobacterium lactis. KBs showed an increased expression the endospore enriched yogurts were very similar to that of
in the first 60 min and decreased thereafter. LPS and the controls. This research was financed by Egerfood Ltd.
probiotic strains to different degrees decreased miRNA and the NKTH research program.
levels, especially miR7i after 6hrs and 24hrs. In dendritic
cells, heat inactivated Lactobacillus GG (LGG) and L.
delbrueckii stimulated an enhanced expression of IL-6, TNFa
and IL-10 mRNA and expression of surface molecules CD86,
CD80,CD83,CD209,CD54 however to a different degree.
Further, in dendritic cells the investigated strains effected
expression of the analysed miRNAs. Discussion: Our results
from CACO II cells and dendritic cells support the hypothesis
that heat inactivated cells from often closely related probiotic
strains or bacteria from the gut differentially induce signaling
pathways, gene expression and miRNAs which epigenetically
control gene expression. Other work of our group, such as
30ORAL C OMM UNI C AT ION S 1
OC1.8 OC1.9
GALACTOOLIGOSACCHARIDES PRODUCTION FROM WHEY DOSE-RESPONSE EFFECT OF BIFIDOBACTERIUM LACTIS
USING ENZYME ISOLATED FROM STREPTOCOCCUS HN019 ON WHOLE GUT TRANSIT TIME AND FUNCTIONAL
THERMOPHILUS AND ASSESSMENT OF THEIR PREBIOTIC GASTROINTESTINAL SYMPTOMS IN ADULTS
POTENTIAL Ouwehand Arthur*[1], Waller Philip[2], Gopal Pramod[3], Leyer
Sangwan Vikas* , Tomar Sudhir Kumar , Ali Babar , Singh
[1] [1] [1]
Greg[4], Reifer Cheryl[5], Stewart Morgan[5], Miller Larry[5]
R.R.B.[1] Danisco Sweeteners - Kantvik, Finland - [2]Accurate Clinical Research
[1]
[1]
National Dairy Research Institute - Karnal, India - Huston, USA - [3]Fonterra - Palmerston North, New Zealand - [4]Danisco
USA - Madison, USA - [5]SPRIM - San Fransisco, USA
1. Production of ß-galactosidase from isolated strains of S.
thermophilus. Slow colonic transit is a common complaint in western
2. Production of prebiotic Galactooligosaccharides (GOS) societies and manifests itself as constipation. It is, however,
using whey as a substrate. also associated with more serious diseases such as various
3. Evaluation of immunomodulatory effect of GOS using mice types of cancer, diverticulitis, gall stones, etc. Various
as animal model. alternative remedies exist to relieve constipation and these
Materials and methods: may have various success. The present study aimed to
1. ß-galactosidase production: S. thermophilus strains assess the impact of Bifidobacterium lactis HN019
isolated from different dairy products were evaluated for the supplementation on total colonic transit time (TCTT) and
production of ß-galactosidase (intracellular). Five different frequency and severity of functional gastrointestinal (GI)
methods viz. lysozyme treatment, SDS-chloroform, symptoms in adults. We randomized 100 subjects (mean
sonication, glass beads and microfluidizer were tried for the age: 44 years; 64% female) with functional GI symptoms to
isolation of enzyme. consume a B. lactis HN019 (Danisco Cultures, Paris), at daily
2. Production of GOS: Lactose is the main substrate for the doses of 17.2 billion colony forming units (CFU) (high dose;
production of GOS. Different concentrations of lactose and n = 33), 1.8 billion CFU (low dose; n = 33), or placebo (n =
ß-galactosidase for varying time periods were used for the 34) for 14 days. The primary endpoint of TCTT was assessed
production of GOS. The HPLC was used for the detection of by X-ray on days 0 and 14 and was preceded by consumption
GOS. of radio-opaque markers once a day for 6 days. The
3. Evaluation of immunomodulatory effect of GOS: Crude secondary endpoint of functional GI symptom frequency was
GOS (produced in the lab) was then evaluated for the its recorded with a subject-reported numeric (1–100) scale
immunomodulatory effect using mice as animal model. Along before and after supplementation. Decreases in mean TCTT
with the immunomodulation, it was also tested for its ability over the 14-day study period were statistically significant in
to reduce the infection caused by Listeria monocytogenes. the high dose group (49 ± 30 to 21 ± 32 h, p < 0.001) and
Results the low dose group (60 ± 33 to 41 ± 39 h, p = 0.01), but not
Among the various methods used for the isolation of ß- in the placebo group (43 ± 31 to 44 ± 33 h). Time to excretion
galactosidase, lysozyme treatment was found to be the best of all ingested markers was significantly shorter in the
one. As it is a chemical method so cannot be used for the treatment groups versus placebo. Of the nine functional GI
production of food grade GOS. Therefore, microfluidizer symptoms investigated, eight significantly decreased in
(found to be the best among mechanical methods) was used frequency in the high dose group and seven decreased with
for the isolation of ß-galactosidase to be used in the low dose, while two decreased in the placebo group. No
production of GOS. The GOS was found to be produced at a adverse events were reported in any group. Daily B. lactis
lactose conc. of 15% and at this conc. max production was HN019 supplementation is well tolerated, decreases TCTT in
observed after 10 hrs of incubation at 400C. The amount of a dose-dependent manner, and reduces the frequency of
GOS production showed a gradual increase with increasing functional GI symptoms in adults. This is one of the few
lactose concentration. In animal model GOS was found to dose-response studies with probiotics; showing a dose
modulate the immune system (Increase in IgG and IgA dependent reduction in colonic transit and functional GI
concentration) along with a significant reduction of L. symptoms. Waller et al. 2011 Scand. J. Gastroenterol. DOI:
monocytogenes infection in mice. 10.3109/00365521.2011.584895
Future projections:
1. Further standardization to increase the maximum amount
of GOS production using whey as substrate is underway.
2. Evaluation of anticancerous effect of GOS.
31You can also read
